Toni Choueiri, MD, on Updated Follow-up Data in RCC at 2021 ASCO

Video

Choueiri detailed combination treatments with follow-up data presented at the 2021 ASCO Annual Meeting.

Toni Choueiri, MD, of the Dana-Farber Cancer Institute, spoke with CancerNetwork® about trials of combination therapies that had updated data presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

Transcription:

There were some studies that were not presented for the first time, but more analysis. So, KEYNOTE-426 [NCT02853331], for example, that [led to the approval of the combination] of pembrolizumab [Keytruda] and axitinib [Inlyta] now has a long median follow-up.

I think one of the issues with these VEGF/IO [immunotherapy] combinations [is that] they never have the same follow up as the IO/IO combinations like nivolumab [Opdivo]/ipilimumab [Yervoy]. Now, pembrolizumab/axitinib has more follow up [and it will] be interesting to look at the data in detail. There are data also for a newer combination of pembrolizumab/lenvatinib [Lenvima] that was presented a couple of months ago. There are data now about quality of life, we know this patient[-reported outcome].

There’s a lot of good stuff to be presented and I hope folks will follow all the data virtually that is coming in renal cell cancer, but also in [genitourinary] cancer in general.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Related Content